Evidence map›Paper›PMID 25672522›Full record

ArticleOncology reports2015

High miR-24 expression is associated with risk of relapse and poor survival in acute leukemia.

Jorge Organista-Nava, Yazmín Gómez-Gómez, Berenice Illades-Aguiar, Luz Del Carmen Alarcón-Romero, Mónica Virginia Saavedra-Herrera, Ana Bertha Rivera-Ramírez, Víctor Hugo Garzón-Barrientos, Marco Antonio Leyva-Vázquez

Open access · bronzeAbstract readComparative Study
In one paragraph

Article in Oncology reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 3 pooled it
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 3 syntheses or guidelines pooled it, 64 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. MiRNAs in Hematopoiesis and Acute Lymphoblastic Leukemia.International journal of molecular sciences · 2023
    Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Identification of Acute Myeloid Leukemia Bone Marrow Circulating MicroRNAs.International journal of molecular sciences · 2020
    Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Jorge Organista-NavaInstitute of Cellular Physiology, National Autonomous University of Mexico (UNAM), University City, D.F., Mexico.
Yazmín Gómez-GómezResearch Department, State Cancer Institute, 'Arturo Beltran Ortega', Acapulco, Guerrero, Mexico.
Berenice Illades-AguiarLaboratory of Molecular Biomedicine, School of Chemical-Biological Sciences, Guerrero State University, Chilpancingo, Guerrero, Mexico.
Luz Del Carmen Alarcón-RomeroLaboratory of Cytopathology, School of Chemical-Biological Sciences, Guerrero State University, Chilpancingo, Guerrero, Mexico.
Mónica Virginia Saavedra-HerreraResearch Department, State Cancer Institute, 'Arturo Beltran Ortega', Acapulco, Guerrero, Mexico.
Ana Bertha Rivera-RamírezResearch Department, State Cancer Institute, 'Arturo Beltran Ortega', Acapulco, Guerrero, Mexico.
Víctor Hugo Garzón-BarrientosResearch Department, State Cancer Institute, 'Arturo Beltran Ortega', Acapulco, Guerrero, Mexico.
Marco Antonio Leyva-VázquezLaboratory of Molecular Biomedicine, School of Chemical-Biological Sciences, Guerrero State University, Chilpancingo, Guerrero, Mexico.
Universidad Autónoma de Guerrero · MXUniversidad Nacional Autónoma de México · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MicroRNAs (miRNAs) play an essential role in the development and progression of acute leukemia (AL). miR-24 promotes the survival of hematopoietic cells. However, little is known concerning the function of miR-24 in human AL. The aim of the present study was to investigate the clinical significance of miR-24 expression in AL. miR-24 expression in 147 patients with AL and 100 healthy individuals was measured by quantitative reverse transcriptase-polymerase chain reaction (RT-qPCR). The results showed that compared with the healthy individuals, the expression of miR-24 in AL patients was significantly higher (p<0.001). In addition, miR-24 was expressed at significantly higher levels in acute myeloid leukemia (AML) patients and at significantly lower levels in acute lymphoblastic leukemia (ALL) (p<0.001). More importantly, Kaplan-Meier analysis showed that AL patients with high miR-24 expression tended to have shorter overall survival (p<0.05). In the multivariate analysis stratified for known prognostic variables, miR-24 was identified as an independent prognostic marker. Our data indicated that miR-24 upregulation was associated with poor prognosis in AL. miR-24 was identified for the first time as an independent marker for predicting the clinical outcome of AL patients.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCase-Control StudiesChildChild, PreschoolFemaleHumansImmunophenotypingKaplan-Meier EstimateLeukemia, Myeloid, AcuteLeukocyte CountMaleMicroRNAsPrecursor Cell Lymphoblastic Leukemia-LymphomaPrognosisReverse Transcriptase Polymerase Chain ReactionBiomarkers, TumorMicroRNAsMIRN24 microRNA, humanRNA, Neoplasm

Identifiers

PMID25672522
PMCPMC4358084
OpenAlexW1978416738

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.